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Abstract
Background: The development of antimalarial drug resistance has led to increasing calls for the introduction of
artemisinin-based combination therapy (ACT). However, little evidence is available on the full costs associated with
changing national malaria treatment policy. This paper presents findings on the actual drug and non-drug costs associated
with deploying ACT in one district in Tanzania, and uses these data to estimate the nationwide costs of implementation
in a setting where identification of malaria cases is primarily dependant on clinical diagnosis.
Methods: Detailed data were collected over a three year period on the financial costs of providing ACT in Rufiji District
as part of a large scale effectiveness evaluation, including costs of drugs, distribution, training, treatment guidelines and
other information, education and communication (IEC) materials and publicity. The district-level costs were scaled up to
estimate the costs of nationwide implementation, using four scenarios to extrapolate variable costs.
Results: The total district costs of implementing ACT over the three year period were slightly over one million USD,
with drug purchases accounting for 72.8% of this total. The composite (best) estimate of nationwide costs for the first
three years of ACT implementation was 48.3 million USD (1.29 USD per capita), which varied between 21 and 67.1
million USD in the sensitivity analysis (2003 USD). In all estimates drug costs constituted the majority of total costs.
However, non-drug costs such as IEC materials, drug distribution, communication, and health worker training were also
substantial, accounting for 31.4% of overall ACT implementation costs in the best estimate scenario. Annual
implementation costs are equivalent to 9.5% of Tanzania's recurrent health sector budget, and 28.7% of annual
expenditure on medical supplies, implying a 6-fold increase in the national budget for malaria treatment.
Conclusion: The costs of implementing ACT are substantial. Although drug purchases constituted a majority of total
costs, non-drug costs were also considerable. It is clear that substantial external resources will be required to facilitate
and sustain effective ACT delivery across Tanzania and other malaria-endemic countries.
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Background
For over a decade, malaria treatment in sub-Saharan
Africa and other endemic regions has been in crisis. Con-
ventional antimalarial drugs such as chloroquine and sul-
phadoxine/pyrimethamine (SP) have become
increasingly obsolete in the face of growing drug resist-
ance. Current debates favour using artemisinin-based
combination therapy (ACT) regimens [1,2]. ACTs are
highly efficacious and offer potential to check the progres-
sion of drug resistance. They are also expensive with prices
as much as 10 to 20 times greater than conventional mon-
otherapies [3,4].
By early 2006, 34 countries in sub-Saharan Africa had
adopted ACTs as first-line treatment for malaria [5,6]. The
region has the largest number of people exposed to stable
malaria transmission and constitutes the greatest burden
of malaria morbidity and mortality in the world with
pregnant women and children under five years being the
most affected groups [7]. Of the 34 countries, only 10
were actively deploying ACT drugs in their public sector
[6] and the majority of malaria patients continue to be
treated with largely ineffective conventional antimalarial
drugs. Despite support from the Global Fund to fight
AIDS, Tuberculosis and Malaria, public health specialists
remain concerned that many countries in Africa are failing
to achieve wide coverage of ACTs. Weak health systems,
chronic under funding of public health services and lack
of trained and motivated health workers are some of the
frequently cited reasons for delays in implementation
[4,8]. In addition, the potential benefits of ACT for inhib-
iting malaria transmission and drug resistance have not
been demonstrated in areas of intense malaria transmis-
sion and severely constrained health infrastructure – pre-
cisely the conditions that prevail in most African
countries.
There is relatively little evidence on the actual costs asso-
ciated with changing national malaria treatment policies
to accommodate ACT. Three studies have provided esti-
mates of ACT procurement costs for Tanzania or Africa
more generally, but none have included other activities
such as training, developing and printing clinical guide-
lines, behaviour change communication (BCC) and pub-
licity materials, or other supplies [9-11]. Moreover the
drug cost estimates in these studies have been obtained
from mathematical models rather than records of actual
financial costs incurred during implementation in a real
world setting. The change in treatment costs at the health
facility level as a result of ACT introduction has been esti-
mated from the patient perspective in Senegal [12], and
from the provider perspective in South Africa [13], but
neither study attempted to document the overall costs of
policy implementation. Only one study has assessed the
non-drug costs of changing national malaria treatment
policy, based on expenditures recorded during the change
from chloroquine to SP monotherapy in Tanzania [14].
However, no studies have systematically documented the
non-drug costs of introducing more expensive and com-
plex ACT regimens. The current study aims to address this
gap.
Policy context
Tanzania is facing the challenge of increasing antimalarial
drug resistance. By the late 1990's chloroquine resistance
had reached unacceptable levels, failing to provide an ade-
quate clinical and parasitological cure in more than half
of the children studied [15,16]. In 2001, the country took
a decision to adopt SP as an interim first-line antimalarial
treatment with a clear intention to search for a more last-
ing solution to the drug resistance problem [17]. As part
of this policy change the Tanzanian Ministry of Health
prioritized operations research to identify a suitable first-
line drug candidate and to gain experience with imple-
menting ACT on a programmatic scale. Among these
efforts was the Interdisciplinary Monitoring Project for
Antimalarial Combination Therapy in Tanzania
(IMPACT-Tz).
IMPACT-Tz was a large-scale study intended to evaluate
the implementation of ACT in a typical rural district with
intense malaria transmission. It involved a comparison of
ACT implementation in Rufiji District (using SP plus
artesunate), with continued use of the national first-line
drug, SP, in two adjacent districts. IMPACT-Tz was one of
the first large scale ACT evaluations in sub-Saharan-Africa
under 'real life' conditions in which ACT was delivered
through existing public health infrastructures with mini-
mal alterations. It aimed to produce robust results, appli-
cable in similar health resource constrained settings in
rural sub-Saharan Africa. The study was explicitly
designed to answer key operational research questions
including those related to: antimalarial drug resistance,
malaria transmission, safety, efficacy, costs and affordabil-
ity, health seeking behaviour, perceptions and commu-
nity attitudes towards ACT use.
In 2004, following initial results from the IMPACT-Tz
study and other sites participating in the East African Net-
work for Monitoring Antimalarial Treatment [18], the
Tanzanian Ministry of Health through the National
Malaria Control Programme (NMCP) declared its inten-
tion to adopt the ACT artemether-lumefantrine (ARLU) as
the national first-line drug to treat uncomplicated
malaria. NMCP submitted an ACT implementation grant
application to the Global Fund which was awarded later
the same year. In 2005, the country began the process of
initiating this second treatment policy change, which cul-
minated in the large scale public sector deployment of
ARLU in December 2006 [19]. Identification of malaria
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cases has remained primarily dependant on clinical diag-
nosis.
This report presents findings from the IMPACT-Tz evalua-
tion on the district-wide costs for three years of activities
deploying ACT in Rufiji District. In addition, the projected
costs of various ACT policy implementation options at the
national level are estimated.
Methods
Study site
Rufiji District is located in Coast Region 178 km south of
Tanzania's commercial capital, Dar es Salaam. The District
covers an area of 13,339 km2, with an estimated popula-
tion of 212,144 [20]. See Figure 1 for detailed location
and distribution of health facilities in Rufiji District.
Annual rainfall ranges between 800–1,000 mm in the
Rufiji River Basin and malaria transmission occurs all year
round, with an entomological inoculation rate of
79–1209 infectious bites per person per year [21]. Malaria
is the leading cause of morbidity and mortality across the
district [22]. According to routine health records, Rufiji
District has one of the highest rates of outpatient consul-
tations for malaria in the country of 826 diagnoses per
annum per 1,000 population [23].
The district has a total of 59 health facilities of which 46
are public, 10 mission-run and only three private for
profit. Public health facilities are managed by the Council
Health Management Team (CHMT) which is based in the
district administrative town of Utete. The health facilities
are managed through eight administrative blocks called
'cascades' with between four to nine health facilities per
cascade. Non-governmental health care providers are
urged to operate within the Ministry of Health and Social
Welfare's standard operating procedures, while receiving
supervision from the CHMT.
Description of the intervention
Artesunate (AS) plus SP was introduced for first-line treat-
ment of uncomplicated malaria at all health facilities in
Rufiji District from February 2003. This particular combi-
nation was introduced not because it was expected to be a
future option for first-line treatment, but because it was
immediately available, provided an ideal opportunity to
gain experience with the ACT approach and could be eval-
uated against SP monotherapy, the recommended first-
line treatment. The design and implementation of the
intervention involved a broad spectrum of activities
encompassing consultation, building consensus, policy
formulation, developing treatment guidelines and other
communication materials, training, procurement, repack-
Map of Rufiji District indicating key health facilitiesFigure 1
Map of Rufiji District indicating key health facilities.
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aging, drug supplies management, and sensitization cam-
paigns. The chronology of these activities is summarized
in subsequent Table 1.
Project team recruitment, consultation and planning
A stakeholders' meeting was held in Dar es Salaam in
October 2002, and key decisions regarding the implemen-
tation process were discussed and agreed [24]. The meet-
ing involved representatives from the research project, the
Rufiji CHMT and the NMCP. Also represented were the
Medical Stores Department (MSD) – responsible for pro-
curement and distribution of essential medicines – and
the Pharmacy Board (which later became the Tanzania
Food and Drug Authority). Secondly, a rapid assessment
of drug management in the district was carried out by
external consultants. Their report documented that drug
storage, distribution and the control of drug inventories
were inadequate and poorly maintained [25]. Attempts
were made to address some of these shortfalls in order to
guarantee smooth implementation of the ACT pro-
gramme. These included new drug stock log-books and
improvements in drug distribution mechanisms to all
health facilities including the most remote. By November
2002, the core project implementation team included the
project implementation manager, one clinician responsi-
ble for tracking reported adverse drug reactions, and an
administrative assistant. Aside from these three project
staff, the rest of the implementation depended on existing
personnel within the Council Health Management Team
and individual health facilities.
Preparation of IEC materials and drug package envelopes
In late 2002, an artist worked with the implementation
team among communities in Rufiji District to develop
communications and dosing instruction illustrations to
aid care-seekers and health workers during drug prescrip-
tion. Five community meetings of between 10 to 30 peo-
ple were held across the district during the design of these
information, education and communication (IEC) mate-
rials. Dosing envelopes showing prescription instructions
were developed for four age groups: children less than one
year, children under-five, school aged children and adults
[26]. These were designed to enhance accurate ACT dosing
practices by both health workers and patients. In addition,
posters and wall charts were developed to explain the ACT
and its correct use at the point of dispensing.
Training
Training of Rufiji District health personnel began in Janu-
ary 2003. The first training involved at least two staff (pre-
scribers and drug dispensers) from all 56 public and
mission health facilities. The training was carried out in a
centrally located primary school over two days. Training
focused on indications and exclusion criteria for the use of
ACT, age specific dosing instructions, and the importance
of emphasising adherence to dosage regimens. Clinicians
were trained to identify severe or cerebral malaria cases
and to abide by national treatment guidelines for such
cases. The training also included a module on identifying
clinical signs of adverse drug reactions resulting from use
of prescribed antimalarial drugs. All training activities
were conducted by the CHMT with assistance from the
IMPACT-Tz project including the principal investigators,
some of whom had experience with national level training
during the 2001 change of national malaria treatment
policy. Following this initial workshop, participants were
charged with conducting similar training sessions with
Table 1: Chronological timeline of ACT program 
implementation in Rufiji District
Start date Activity
Sep-02 Appointment of implementation manager marking 
the formation of the core project implementation 
team
Oct – Dec-02 Planning meetings & development of IEC* materials
Nov-02 Rapid assessment of drug requirements, storage, 
distribution and consumption in Rufiji District
Dec-02 – Jan-03 First and second pre-testing of IEC* materials
Jan-03 First printing of posters and training
Jan-03 First consignment of drugs delivered to Kibiti 
health centre
Feb-03 Training of health personnel from the 56 district 
health facilities
Apr-03 Local leakage consultant hired to review drug 
supplies mechanisms in Rufiji District
Jun-03 Second printing of posters
Jun-03 Second drug consignment delivered to Kibiti health 
centre
Aug-03 Public Launch of new treatment policy in Rufiji 
District
Aug-03 Third drug consignment delivered to the 8 cascade 
supply stations
Sep-03 Fourth drug delivery to the cascades including 
health facilities in the peripheral areas
Nov-03 Fifth drug delivery
Jan-04 Re-packaging of drugs began
Feb-04 Community meetings
Feb-04 Third printing of posters
Feb-04 Sixth drug delivery
Apr-04 Seventh drug delivery
May-04 Adverse drug reaction training
Jun-04 Strengthening of various measures to mitigate drug 
leakages
Jun-04 Eighth drug delivery
Sep-04 Ninth drug delivery
Oct-04 Training of school teachers and community leaders
Jan-05 Tenth drug delivery
Feb-05 Refresher training of health personnel from 56 
district health facilities
Feb-05 Integration of malaria awareness campaigns into 
primary school program
May – Jul-05 11th, 12th and 13th drug delivery
Aug – Sep-05 Last community sensitization meetings throughout 
the district
*IEC = Information, education and communication
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health facility staff under their supervision upon returning
to their posts. A follow-up training (refresher course) was
conducted 18 months after initial ACT introduction, and
later that year a separate training course was organized on
adverse drug reactions for supervising health workers at
all facilities.
Training for community leaders and primary school
teachers was conducted two years after ACT introduction
to increase awareness in the community and sensitize
communities to the health and socio-economic conse-
quences of malaria. Project staff trained supervising clini-
cians at each of the eight administrative blocks (cascades)
who then went on to train 104 primary school teachers
and 16 ward community leaders as well as volunteer vil-
lage health workers.
Drug procurement and distribution
Between January 2003 and September 2005 over 450,000
adult doses of ACT were deployed to public and mission
health facilities in Rufiji District. MSD continued to sup-
ply SP in the district, while the project procured artesu-
nate. Because no co-formulated or co-packaged product
was available, the drugs were co-administered at the
health facility level. Artesunate tablets (Arsumax® 50 mg,
Sanofi-Aventis, Gentilly, France) were purchased from a
single European supplier at an internationally negotiated
discount price. The first consignment of artemisinin drugs
was delivered to Kibiti Health Centre in January 2003.
Kibiti was chosen as a delivery point because all MSD
drugs were delivered to this centre, from where they were
collected by the cascades and taken to their respective
health facilities. For this initial consignment, the district
health management team was responsible for ensuring
drug distribution to each health facility.
To optimize adherence to recommended dosing regi-
mens, the first ACT dose was directly observed at the
health facility. Supplies purchased to facilitate this
included vessels for clean water, drinking cups, spoons,
knives for cutting tablets, water purifying solution and in
some facilities bottles of drinking water. ACT was freely
available to all malaria patients seeking care in all public
and mission (not for profit) health facilities in Rufiji Dis-
trict.
Combating drug leakages
In April 2003, following reports that artesunate tablets
purchased for the project had been found in shops in Dar
es Salaam, an inventory management consultant was
hired to work with the project manager. After careful eval-
uation of the whole drug delivery process, the consultant
recommended measures to reduce the risk of future mis-
direction of medicines. These included the introduction
of drug stock audit books for all health facilities receiving
project drugs, routine and random audits of drug stock
inventories at all levels of the system, and the delivery of
artesunate drugs directly to the eight cascades by project
vehicles from Dar es Salaam rather than the central point
in Kibiti.
Another measure to curb drug leakage involved hiring
part time workers in Dar es Salaam to pack the artesunate
into large boxes marked with health facility names and
the total number of doses the facility was to receive. A
'mystery shopper' also visited shops and private health
facilities in Rufiji and Dar es Salaam to identify any ven-
dors illegally stocking project drugs.
Communication and publicity
In August 2003, a major public launch of ACT was held in
Ikwiriri, the largest market center in Rufiji District. This
public event was attended by diplomats, politicians and
public health officials, journalists and media representa-
tives. The event included community sensitization activi-
ties, involving live music, theatre, performing artists and
road show vehicles that visited communities across the
district. The public launch was followed by a series of
community sensitization meetings carried out by the
project team in collaboration with the CHMT and com-
munity leaders. The last sensitization meeting in August/
September 2005 was judged to mark the end of ACT
implementation activities in Rufiji District and the start of
the transition to ARLU.
Costing methods: district study
The main objectives of the costing study were to a) docu-
ment the financial costs of introducing an ACT in a typical
malaria endemic district of rural Tanzania, and b) esti-
mate the costs of national implementation. The costing
approach was incremental in the sense that it excluded the
costs of health facility infrastructure, supervision and staff,
which were assumed not to change as a result of the intro-
duction of a new drug. All costs are presented in 2003
prices in Tanzanian shillings and US dollars, based on an
exchange rate of 1 USD: TZS 1065 [27]. The 2004 and
2005 prices were deflated to 2003 price values using the
annual inflation rates of 4.2 and 4.5 percent, respectively
[28].
Costs were calculated from the provider perspective,
including only those costs incurred by the public health
sector or the project. No Ministry of Health and Social
Welfare costs above the district level were included,
reflecting the emphasis on decentralization of manage-
ment functions to districts. Costs to households were
excluded, but are not expected to have been significantly
different from those incurred under monotherapy.
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The timeframe for the costing exercise was defined as the
three year period from the initial stakeholders' meeting in
October 2002 to the last sensitization meeting held in
August/September 2005. This period was selected as it
covered all the set up activities needed to implement ACT,
and avoided overlap with preparations for nationwide
introduction of artemether-lumefantrine, for which initial
preparations began in late 2005. Including drug costs for
the three year period allowed for year on year variation in
malaria prevalence, health facility utilization and drug use
to be included, an important element seldom considered
when estimating national ACT needs from models alone.
This study presents both ACT programme implementa-
tion set-up costs and recurrent costs. Set-up costs were
defined to include all activities required to introduce the
new policy, which were not repeated regularly. They
included costs related to the project implementation team
(including local and international consultancy fees), pur-
chase of office equipment (minor capital goods such as
computers, vehicles, motorbikes, printers and a mobile
radio station), development of IEC materials (including
the time of the artist and research team, refreshments for
focus group participants etc), and training of health per-
sonnel (including transport allowances and per-diems,
training venue, refreshments, and training materials etc.).
In addition, set-up costs incorporated communication
and publicity activities mainly directed to the general pub-
lic which included road shows, community sensitization
meetings, the programme launch and sensitization mate-
rials such as stickers, road signs, posters and t-shirts. Most
set-up costs were incurred in the first year, with the excep-
tion of some additional training courses and community
sensitization meetings. Recurrent costs encompassed drug
purchase and distribution and other supplies including
stationery and office supplies, drug repackaging materials
including prescription envelopes, water treatment solu-
tion, buckets, scissors, and drug audit books.
The ACT used in the study was not co-formulated. As
described above, artesunate was bought separately by the
project and co-administered together with SP drugs which
were delivered through normal drug delivery channels
within the district. SP quantities were collected from drug
supply log books across Rufiji District and cross-checked
against numbers obtained at the MSD headquarters. The
SP drugs were valued at prices provided by MSD, plus
14% transport and distribution charges (standard MSD
charging practice for mainland Tanzania).
Cost data were drawn from both expenditure and budget
records, routinely documented and maintained by the
project accountant who was informed from the start that
comprehensive records would be required for the costing
exercise. Additional information was obtained through
interviewing the IMPACT-Tz project implementer, the
accountant, the principal investigators and key district
health personnel. Care was taken to exclude research
costs, but to include all activities necessary for implemen-
tation, including the time of project staff spent on imple-
mentation and monitoring activities.
Annualized costs for goods with a lifespan of more than a
year were calculated using a 5% discount rate. Vehicles
were estimated to have a lifespan of 10 years, motorbikes
and the mobile radio base station five years, and comput-
ers and printers three years.
Estimating the costs of national level ACT implementation
The district costs were then extrapolated to estimate the
costs of national level implementation for the Tanzanian
mainland. It was assumed that all mainland Tanzania
would need ACT because the entire country is at risk of
malaria [29]. The islands of the Zanzibar Archipelago
were excluded because they are governed by an autono-
mous administration with its own Malaria Control Pro-
gramme and a distinct antimalarial treatment policy. It
was assumed that ACT deployment would follow current
public health treatment practices where drugs are largely
offered for free in most public health facilities, while the
mission facilities continue to offer services on a not-for-
profit basis.
Since the Ministry of Health and Social Welfare has
adopted ARLU as its nationwide treatment recommenda-
tion, all national cost estimates were based on ARLU pro-
curement costs recently announced by the manufacturer
(Novartis® Pharma, Basel, Switzerland), ranging from 0.45
USD for children under five to 1.8 USD per adult dose
[30]. Unlike SP+AS, ARLU is available in a co-formulated
tablet packaged in unit-doses specifically designed for
four age or weight groups. However, ensuring these reach
each health facility in appropriate ratios will require addi-
tional repackaging. It was assumed that this could be
accomplished with a level of effort similar to repackaging
SP+AS that occurred in the intervention district. The
breakdown of malaria outpatient diagnoses by age group
was estimated based on IMPACT-Tz 2004 household sur-
vey data (Table 2) (IMPACT-Tz unpublished data).
Scenarios for estimating national costs
For the purpose of estimating national costs, all activities
were divided into fixed and variable items (which differed
from the earlier categorization of set-up and recurrent).
Fixed costs were those that were not expected to vary by
scale of implementation, and included the project imple-
mentation team, office equipment and the development
of IEC materials. Costs for IEC materials and office equip-
ment were based directly on those incurred in Rufiji Dis-
trict. For the costs related to the project team, the
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approach used in the 2001 study on antimalarial drug
policy change from chloroquine to SP was adopted [14],
assuming that a similar team (including eight months
expatriate time) would be used for nationwide ACT
deployment. Personnel costs for the implementation
team included 15 months each for the programme and
deputy programme manager, the eight months expatriate
time, 16 months for a technical officer, 19 months for a
supplies assistant, 21 months for a data manager and 84
months of health officer time.
Nationwide variable costs related to drug purchase and
distribution, other supplies, training, communication and
publicity were estimated by scaling up variable costs
incurred in Rufiji District according to four different sce-
narios, as described below. The one exception was drug
distribution costs. As distribution on a nationwide scale
would necessarily be undertaken through MSD, distribu-
tion costs were based on the MSD standard rate of 14% of
drug purchase costs.
Scenario I – scaling up by number of districts
Rufiji District variable costs were scaled up by the number
of districts in mainland Tanzania (119). This approach
assumes that districts are uniform, ignoring variations in
population, outpatient malaria diagnoses, number of
health facilities etc.
Scenario II – scaling up by population
Rufiji District variable costs per capita were scaled up by
the total estimated population of mainland Tanzania:
37,491,094 in 2007 (projected from the 2002 national
census, at a growth rate of 2.3% [20]). Given the varia-
tions in outpatient malaria diagnoses across districts, this
may lead to biased results, especially as Rufiji District has
a relatively high outpatient malaria diagnosis rate of 826
per 1,000 compared with a national average of 390 per
1,000 [23].
Scenario III – scaling up by malaria outpatient diagnoses
Rufiji District variable costs per malaria outpatient diag-
nosis were scaled up by the total reported malaria outpa-
tient visits for the Tanzanian mainland: 10,940,628 in
2003 (the most recent year for which complete data were
Table 2: Parameters used in estimation of nationwide costs and sensitivity analysis
Calculation Parameters
Rufiji District Parameters Source/Ref. Number
Total Rufiji District population 212,144 NBS Ref # 20
Malaria outpatient cases per 1000 population in Rufiji District 826 NMCP Ref # 23
Total public health facilities in Rufiji District 46 Rufiji CHMT
Total mission health facilities in Rufiji District 10
Total ACT (AS + SP) doses deployed over 3 years in Rufiji District 445,944 IMPACT-TZ Annual Reports
National Parameters for Tanzania Mainland
National population growth rate per annum 0.023 NMCP Ref # 23
Total population in Tanzania (2002 census) 33,461,849
Malaria outpatient cases per 1000 population 390
Total number of Districts in mainland Tanzania 119 NBS Ref # 20
Total number of public health facilities in mainland Tanzania 3,456 Ministry for Health & Social Welfare, Tanzania
Total number of mission health facilities in mainland Tanzania 951
MSD handling and distribution costs as proportion of drug costs 0.14 Medical Stores Department
Drug Cost Parameters
Average cost of AS+SP per dose TZS. 1,870 IMPACT-Tz
Average cost of ARLU per dose TZS. 1,266 Implementation costs ef # 28
Proportions of malaria patients by age group:
Age between 3 to 36 months 0.34
Age between 37 to 84 months 0.15 IMPACT-Tz 2004
Age between 7 to 14 years 0.06 household survey
Age from 15 years and above 0.45
Sensitivity Analysis
Cost of six deputy managers (3 years salary and benefits) 70,986 USD Ref # 14 (New salary schemes)
Total Expatriate costs 36,672 USD Ref # 14
Additional office equipments 250,072 USD IMPACT -Tz. purchase records
Projected increase in public and mission health facility utilization following 
introduction of ACT
50% IMPACT-Tz. Surveys
Average cost per dose of cheaper alternative ACT (AS+Amodiaquine) 0.85 USD 1st line drug of choice in Zanzibar
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available) [23]. The major shortfall of this approach is the
unreliability and incompleteness of outpatient data
reported through the national health management and
information system.
Scenario IV – composite estimation
The three scenarios above use a common base to scale up
all costs. This has the advantages of simplicity and clarity.
However, in reality different bases will be appropriate for
different cost components, depending on their key cost
drivers. For example, drug costs will be mainly dependent
on number of patients, but training costs will be driven
more by staff numbers. A composite scenario was there-
fore calculated as follows, using the most appropriate base
for each cost category:
• Project team costs based on 2001 policy change from
chloroquine to SP (adjusted for inflation) [14]
• Office equipment costs based on Rufiji District costs
• Development of IEC materials based on actual costs
incurred in Rufiji District
• Training of health personnel costs scaled up by multi-
plying Rufiji District costs per health facility by the total
number of registered public and mission health facilities
in mainland Tanzania
• Drug purchase and other supplies costs scaled up by
multiplying Rufiji District costs per reported malaria out-
patient diagnosis by the total national outpatient malaria
diagnoses per year reported by the Health Management
Information System for all registered public and mission
health facilities in mainland Tanzania
• Communication and publicity costs scaled up by multi-
plying Rufiji District per capita costs by the total popula-
tion in mainland Tanzania.
From a theoretical perspective we would consider this sce-
nario to be the best estimate of nationwide costs.
In addition, one-way sensitivity analyses were carried out
with respect to three key areas: implementation team per-
sonnel, increase in health facility utilization, and the use
of an alternative less costly ACT. All parameters in the sce-
narios and sensitivity analyses are presented in Table 2.
Ethical clearance
This study received ethical approval from the institutional
review boards of the Ifakara Health Research and Devel-
opment Centre, the Tanzanian Medical Research Coordi-
nating Committee, the London School of Hygiene and
Tropical Medicine, and the US Centers for Disease Con-
trol and Prevention.
Results
Costs of Rufiji District implementation
The costs of deploying ACT in Rufiji District are presented
in Table 3 and Figure 2. Results are presented over a
period of three years and categorized into set-up and
recurrent costs. The total cost for implementing ACT in
the district was TZS 1,105,242,773 (1,037,787 USD). Set
up costs accounted for 20.3% of total costs over the three
years, mainly concentrated in year one, though they con-
tinued into years two and three to cover refresher training
for health workers and training of council health manage-
ment teams and primary school teachers. Overall, the
most costly set-up items were personnel costs of the
project implementation team and consultancy fees, fol-
lowed by communication and publicity, the costs of
developing and producing various IEC materials, and
finally office equipment (which included use of a four
wheel drive vehicle to supervise implementation). Recur-
rent costs were fairly constant across the three years, with
slightly higher costs in the second year, reflecting an
increase in facility utilization and the costs of addressing
drug leakage. Overall costs declined over time. The rela-
tively low drug purchase costs in year 3 reflect the use of
drugs purchased in the preceding years. The majority of
overall costs were related to drug purchase and importa-
tion handling charges.
Newly announced prices for ARLU are lower than what
the project was able to negotiate for the purchase of
artesunate plus SP. As ARLU has been chosen to be the
national first-line antimalarial drug, the results in Rufiji
were re-estimated by replacing artesunate plus SP costs
with those of ARLU. This led to a reduction of drug pur-
chase costs by 32%, from 755,659 to 529,982 USD. Sub-
stituting present-day prices of ARLU for the actual costs
incurred purchasing artesunate and SP reduced overall
costs of ACT implementation in Rufiji by 22% from
1,037.787 to 807,820 USD over the three year period.
Scaling up to the national level
Estimated national level costs based on the four scenarios
described above are presented in Table 4. Total costs for
the first three years of implementation varied from 43.1 to
121.7 million USD, implying a per capita cost of 1.15 to
3.25 USD. Scenario two (scaling up by population) led to
the highest cost estimate followed by scenario one (scal-
ing up by number of districts). Scenario three (scaling up
by outpatient malaria diagnoses) led to the lowest esti-
mated costs. In Composite Scenario four (considered the
best estimate) the costs amounted to 48.3 million USD.
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In all four scenarios the single greatest cost was for drug
purchase, accounting for between 68.6% and 77.0% of
total costs. In scenarios one, two and three, drug purchase
costs were followed by drug distribution (around 10.8%).
In Composite Scenario four communication and public-
ity was the second largest cost category (15.5%), followed
by drug distribution (9.6%). All other costs were well
below 10% of total costs in all scenarios.
Sensitivity analyses
Based on the best estimate (Composite Scenario four), we
undertook a number of one-way sensitivity analyses, cov-
ering strengthening the NMCP implementation team,
increased facility utilization, and alternative use of a more
affordable ACT. Results are summarized in Table 5.
Strengthening NMCP team capacity
During the implementation of the 2001 policy change
from chloroquine to SP, concerns were raised about the
capacity of the NMCP team to implement their pro-
gramme effectively [14]. The impact on implementation
costs was therefore examined of strengthening the NMCP
team by establishing five zonal implementation teams. In
each zone the teams would comprise a full-time zonal
implementation manager, a technical officer, an office
assistant, and two health officers, and would each be pro-
vided with three months expatriate time to support the
Costs of implementing ACT in Rufiji district (2003 prices)Figure 2
Costs of implementing ACT in Rufiji district (2003 prices).
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Table 3: Total costs of implementing ACT in Rufiji district (TZS and USD, 2003 prices)
COST TYPE Year One Year Two Year Three Grand Total %
Set up costs (Tshs)
Project 
implementation team 
& consultancy fees
37,443,438 26,852,700 20,248,544 84,544,682 7.6%
Office Equipments 11,152,386 11,152,386 11,152,386 33,457,158 3.0%
Development & 
Production of IEC 
materials
22,312,540 11,626,570 4,044,711 37,983,821 3.4%
Training of health 
personnel
8,161,000 4,616,123 10,523,561 23,300,684 2.1%
Communication and 
publicity
31,339,600 6,715,355 6,923,259 44,978,214 4.1%
Total set up costs 
(TZS)
110,408,963 60,963,134 52,892,460 224,264,558 20.3%
Set up costs (USD) 103,670 57,242 49,664 210,577
Recurrent costs (Tshs)
Drug purchase and 
port handling charges
274,689,940 316,971,141 213,115,713 804,776,794 72.8%
Drug distribution 
costs
23,227,950 19,693,807 12,568,885 55,490,642 5.0%
Other supplies 7,541,600 6,323,289 6,845,890 20,710,780 1.9%
Total Recurrent 
costs (TZS)
305,459,490 342,988,237 232,530,488 880,978,215 79.7%
Recurrent costs 
(USD)
286,816 322,055 218,338 827,210
Grand total (TZS) 415,868,453 403,951,371 285,422,948 1,105,242,773 100%
Total costs (USD) 390,487 379,297 268,003 1,037,787
Per capita cost 
(USD)
1.84 1.79 1.26 4.89
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establishment of the zonal offices. In addition the
national deputy manager post was increased to a full-time
job to allow for the additional supervisory activities, and
funds were included for supervision of the zonal offices by
the national NMCP team, and for zonal office costs.
Finally, NMCP salaries were revised based on the new civil
servants salary scheme adopted in 2005. Other personnel
costs were assumed to remain as recorded in Mulligan et
al. This increased the NMCP personnel costs from 82,818
USD to 290,366 USD. The establishment of zonal imple-
mentation teams also increased office equipment costs by
almost nine times to 281,487 USD. This led to an increase
in overall ACT implementation costs in Composite Sce-
nario four model of 0.9%.
Increased health facility utilization levels
Household surveys in Rufiji District have shown that after
ACT implementation, overall health facility utilization
increased from 29% of all care seeking visits for febrile ill-
nesses in 2002, to 43% in 2004 (IMPACT study, unpub-
lished data), which is likely to have reflected awareness
that a highly effective antimalarial was available at health
facilities. Significant increases were especially noticed
among patients aged five years and above. It is, therefore,
likely that nationwide provision of a similarly effective
antimalarial drug would also increase utilization of public
and mission health facilities, assuming that subsidized
ACT is not available in the private-for-profit sector. In the
sensitivity analysis it was assumed that there would be a
50% increase in national drug purchase costs, which in
turn would increase the costs of drug distribution and
other supplies. This led to an increase of 39% in overall
Table 5: Sensitivity analysis results for costs of nationwide implementation (using Composite Scenario IV as base case, 2003 USD)
Activities Base Case
(Composite Scenario IV)
Strengthening the
Implementation team
Increased Facility
utilization
Cheaper ACT
Implementation team 82,818 290,366 82,818 82,818
Office equipments 31,415 281,487 31,415 31,415
Development of IEC Materials 35,666 35,666 35,666 35,666
Training 1,721,766 1,721,766 1,721,766 1,721,766
Total Drug purchase 33,089,679 33,089,679 49,634,518 9,245,601
Drug Handling & Distribution 4,632,555 4,632,555 6,948,833 1,294,384
Communication & Publicity 7,463,627 7,463,627 7,463,627 7,463,627
Other supplies 1,214,166 1,214,166 1,214,166 1,214,166
Total (USD) 48,271,692 48,729,312 67,132,809 21,089,443
Total (TZS) 51,409,351,760 51,896,717,192 71,496,441,307 22,460,256,995
Percentage change +0.9% +39.0% -56.0%
Table 4: Summary of costs of three years nationwide implementation of ACTs based on different cost scenarios (2003 USD)
Scaled up by:
Number of districts Population Number of malaria outpatient diagnoses Variety of bases (see text)
Activities: Scenario I % Scenario II % Scenario III % Scenario IV %
Project team 82,818 0.10 82,818 0.07 82,818 0.19 82,818 0.17
Office Equipments 31,415 0.04 31,415 0.03 31,415 0.07 31,415 0.07
IEC development & 
production
35,666 0.04 35,666 0.03 35,666 0.08 35,666 0.07
Training 2,603,551 3.18 3,866,486 3.18 1,365,999 3.17 1,721,766 3.57
Drug purchase 63,067,875 76.92 93,660,959 76.97 33,089,679 76.79 33,089,679 68.55
Drug distribution 
costs
8,829,503 10.77 13,112,534 10.78 4,632,555 10.75 4,632,555 9.60
Communication & 
publicity
5,025,735 6.13 7,463,627 6.13 2,636,841 6.12 7,463,627 15.46
Other supplies 2,314,162 2.82 3,436,720 2.82 1,214,166 2.82 1,214,166 2.52
Total (USD) 81,990,724 100. 121,690,225 100. 43,089,138 100. 48,271,692 100
Total (TZS) 87,320,120,918 129,600,089,890 45,889,932,230 51,409,351,760
Per capita cost 
(USD)
2.19 3.25 1.15 1.29
Malaria Journal 2008, 7:4 http://www.malariajournal.com/content/7/1/4
Page 11 of 14
(page number not for citation purposes)
ACT implementation costs, suggesting that changes in
treatment seeking could have a major impact on total pro-
gramme costs.
Use of an alternative ACT
Finally, the use of a less expensive ACT such as artesunate
plus amodiaquine was considered. This combination was
chosen because it is currently being used in neighbouring
Zanzibar as first line drug for treating uncomplicated
malaria, with an average cost of 0.85 USD per dose. At this
relatively cheaper purchase price, there would be propor-
tionate reduction of drug distribution costs but all other
costs would remain constant. This led to a 56% reduction
in the overall costs estimated for implementing ACT
nationwide.
Discussion
Given the rise in antimalarial drug resistance and subse-
quent introduction of new malaria treatment recommen-
dations, it is important to understand the costs of
changing antimalarial drug policy in order to facilitate
planning by national governments and their donor part-
ners, and as an input into evaluations of the cost-effective-
ness and affordability of new drug policies. Studies to date
on the national costs of ACT implementation have
focused on drug costs [9-11,31] in one case including
other case management costs at facility level [13]. No pre-
vious studies have fully documented the drug and non-
drug costs involved in national policy change to ACT.
More importantly, this study is based on data from actual
costs incurred during district-wide ACT implementation
under real life conditions, in contrast to previous esti-
mates derived from models.
The total cost of three years of ACT implementation in
Rufiji District was 1,037,787 USD or USD 4.89 per capita.
Depending on the approach used to scale up costs, the
nationwide costs of the first three years of ACT implemen-
tation were estimated to be between 43.1 and 121.7 mil-
lion USD, with the best estimate at 48.3 million USD
(1.29 USD per capita). This varied between 21.1 and 67.1
million USD in the sensitivity analyses. In all estimates
drug costs constituted the majority of total costs. How-
ever, non-drug costs such as office equipment, IEC mate-
rials, drug distribution, communication, and health
worker training were also substantial, accounting for
31.4% of overall ACT implementation costs in the best
estimate scenario. Of these non-drug costs, the most
expensive were communication and publicity and drug
distribution.
In terms of affordability, the implications of ACT imple-
mentation for the health budgets of countries like Tanza-
nia are considerable. Tanzania's total health budget
(recurrent and development) in 2005 amounted to 254.6
million USD of which 169.3 million USD was allocated
for recurrent expenditures, with only 56 million USD
remaining for medical supplies [32]. Over 90% of Tanza-
nia's total health development budget is funded through
donor support. Between 25 to 45% of the recurrent
budget in Tanzania is funded through donor support [33].
Based on Composite Scenario four estimates, the average
annual costs of the first three years of national ACT imple-
mentation would be equivalent to 9.5% of Tanzania's
recurrent health budget, 6.3% of the total health budget
(recurrent and development), and 28.7% of total expend-
iture on medical supplies. The total expenditure on anti-
malarial drugs in 2005 (USD 1.7 million) would cover
only 15.4% of annual ACT drug cost estimates. In view of
these scant resources, in 2005 the Global Fund approved
a grant of 54.2 million USD to help Tanzania roll out
ACTs over a two year period (to cover drug costs and sup-
porting activities) [34]. According to Composite Scenario
four, the Global Fund resources would be enough to sup-
port ACT policy change for a period of three years.
Resources are yet to be identified to sustain the country's
policy decision in subsequent years.
These results can be compared with two previous studies
in Tanzania. One calculated the non-drug costs of policy
change from chloroquine to SP monotherapy; while the
other estimated the drug costs of policy change from SP
monotherapy to combination therapy (all results have
been converted to 2003 USD to facilitate comparison).
The first study by Mulligan and colleagues was a post-hoc
evaluation of the 2001 policy change from chloroquine to
SP, which estimated the nationwide non-drug costs of
implementation at 734,441 USD [14], compared with
estimates in Composite Scenario IV of non-drug costs
which are over 20 times higher at 15,240,144 USD. For
example, Mulligan and colleagues reported the average
cost per district to be 2,878 USD for training, and 1,483
USD for communication and publicity, compared with
the estimates from Rufiji District of 21,879 USD and
42,233 USD respectively. There are a number of possible
reasons for these substantial differences. First, it is highly
likely that the costs captured were more comprehensive in
this study than for the 2001 policy change. The costs in
this study were based on thorough data collection at the
district level and relied on detailed accounts data and
other records established to track costs associated with the
delivery of the ACT from the start of the project. In con-
trast, Mulligan and colleagues estimated the cost of the
policy change after the fact and at the macro level. More-
over, the previous study covered the period from 1999
when the Ministry of Health formally cleared the policy
change process to August 2002; one year after policy
implementation began. The three year period used in this
study, therefore, had more comprehensive coverage of
costs incurred during post implementation. Secondly, the
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scope of implementation activities carried out in Rufiji
District was broader than those documented for the 2001
policy change, including for example, refresher training
for health workers, integration of malaria issues into the
primary school curriculum, and intensive communication
and publicity activities not matched during the 2001 pol-
icy change. One could argue that more intensive activities
were warranted to support the introduction of combina-
tion therapy compared with a change between two mon-
otherapies, reflecting the more complex dosing regimen,
and imperative to ensure good use of these more expen-
sive drugs.
Secondly, a USAID commissioned study by Wolf and Der-
riennic estimated the projected ACT financing gap for
mainland Tanzania in 2007 assuming that ACT was pro-
vided through all public and non government facilities,
and that 70% of all fever cases were treated in such facili-
ties [11]. The study included drug costs only, evaluating
three ACT regimens. It found that the country would need
42.4 million USD per annum to purchase ARLU drugs,
14.6 million USD for artesunate plus amodiaquine, and
19.7 million USD for piperaquine/dihydroartemisinin/
trimethoprim (2003 prices). By contrast, the Composite
Scenario IV estimate of nationwide ARLU drug costs over
three years through the same facilities was 33 million
USD, giving an annual average drug cost of 11 million
USD, only 24% of the ARLU costs modelled by Wolf and
Derriennic. In the sensitivity analysis the estimated drug
costs with a more affordable ACT were 9.2 million USD
over three years, or 3 million USD per year, compared to
the Wolf and Derriennic estimate of 15.5 million USD
with artesunate + amodiaquine. There are two major rea-
sons for the substantial differences. One is that Wolf and
Derriennic used an older average price per dose for ARLU
of 1.57 USD while the current study used a recently nego-
tiated price averaging 1 USD. Wolf and Derriennic esti-
mated their more affordable alternative ACT at 1 USD
whereas a more up-to-date average of 0.85 USD per dose
was used in this study. In addition, the estimates pre-
sented here are based on actual treatment seeking patterns
observed in Rufiji District. Although their estimates of
fever incidence were based on IMPACT data from study
sites including Rufiji District, their assumption that 70%
of fever cases will be treated in formal-sector health facili-
ties was not. The 70% figure above is far above the rates
observed in Rufiji District either before or after the intro-
duction of ACT (29% and 43% respectively), even though
Rufiji District treatment seeking estimates were obtained
from household surveys carried out in an area of holoen-
demic malaria transmission during the rainy season when
malaria transmission typically peaks.
There are a number of reasons why nationwide cost esti-
mates based on the experience implementing ACT in Ruf-
iji District could be expected to overestimate costs for the
country as a whole. Firstly, though care was taken to main-
tain 'real life' implementation conditions, the experience
in Rufiji District could be considered to represent best
practice as it was relatively well-funded, implemented by
a highly motivated team and closely monitored. This is
likely to have led to a more comprehensive implementa-
tion programme beyond what might be expected during
routine implementation on a larger scale. Secondly, the
ACT used in Rufiji was not co-formulated or co-packaged
in one blister pack. This may have necessitated greater
resources for additional packaging, IEC and communica-
tion than would be required with a co-formulated product
such as ARLU. Thirdly, a significant proportion of the Ruf-
iji District population lives in the relatively inaccessible
delta area, where the costs of accessing some health facili-
ties and communities are particularly high. Finally, poten-
tial savings arising from the use of a more effective drug
were not included, such as a decline in severe cases and
thus reduced costs of inpatient admissions.
On the other hand, using the actual costs incurred in Ruf-
iji District could equally have led to underestimation of
nationwide costs. Firstly, it is likely that the potential for
leakage of ACT supplies to private for-profit outlets would
be much greater with national level implementation, thus
leading to substantial increases in drug and drug distribu-
tion costs. Secondly, with national implementation there
is the potential to use the mass media for publicity cam-
paigns, which is not feasible on a district level, which in
turn could increase implementation costs. Thirdly, Rufiji
District is relatively close to Dar es Salaam, facilitating the
management of drug distribution and other implementa-
tion activities. Moreover, Rufiji District has benefited from
the presence of the Tanzania Essential Health Intervention
Project (TEHIP) which has helped strengthen the district
health system – greater resources might be required to
ensure effective management in other settings. Finally, the
costs were estimated on an incremental basis; in some set-
tings more fundamental health system strengthening may
be required to ensure efficient roll out, such as the recruit-
ment of additional health workers, or improvement of
storage facilities to accommodate the shorter life span and
bulkier packaging of ACT drugs.
A final limitation is the reliance on malaria outpatient
diagnoses data as a base for scaling up all costs in Scenario
three and some costs in Scenario four. As in many devel-
oping countries, these routine health information system
reports are often inaccurate and incomplete. This has a
potentially important impact on the cost estimates as the
number of malaria diagnoses is the major determinant of
Composite Scenario four estimate of national drug
requirements, which in turn are the major driver for total
ACT deployment costs.
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This study's ACT cost estimates were based on the current
mode of ACT implementation in Tanzania which involves
ACT provision through public and private not-for-profit
health facilities only, in most cases on the basis of clinical
diagnosis alone. Clinical diagnosis is known to lead to
substantial over-treatment with antimalarial drugs
[35,36], and the high costs of ACTs and concern about
excessive drug pressure have led to calls for improvements
in malaria diagnosis by extending the use of microscopy
and rapid diagnostic tests (RDTs). The impact of increased
reliance on parasite-based diagnosis on implementation
costs is beyond the scope of this paper but would be
affected by malaria parasite prevalence, diagnostic accu-
racy, the cost of the test and prescribing behaviour of cli-
nicians particularly when faced with a negative test result
[35,37]. In addition, there have been calls for ACT cover-
age to be expanded through the use of private retailers
such as drug shops, and/or village health workers [38,39].
This would require a substantial increase in non-drug
resources to cover additional activities such as training
and communication, and if successful in increasing cover-
age, could also lead to major increase in total drug costs.
Conclusion
This study has improved the evidence base for govern-
ments on the incremental financial costs of ACT imple-
mentation. The estimates were based on a detailed
assessment of costs incurred during district-wide imple-
mentation in a typical rural district, and the extrapolation
of these data to estimate nationwide costs. They included
both drug and non-drug costs, such as IEC materials,
training of health personnel, communication, drug distri-
bution, other supplies and the project implementation
team.
The costs are substantial, with a best estimate of 48.2 mil-
lion USD (1.29 USD per capita) over the first three years.
The total overall costs varied between 21 and 67.1 million
USD in the sensitivity analysis. The study highlights three
key messages. Firstly, drug costs constituted the majority
of total costs, but non-drug costs were also considerable,
accounting for 31.4% of overall costs in Composite Sce-
nario IV estimate. Secondly, rolling out ACTs would lead
to a more than 6-fold increase in the national budget for
antimalarial drugs. Thirdly, average annual implementa-
tion costs over the first three years would be equivalent to
9.5% of the total health sector recurrent budget. It is thus
clear that substantial external resources are required to
facilitate implementation of ACT, particularly in the early
years of implementation, but also to ensure the sustaina-
bility of effective provision of malaria medicines.
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